Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

nivolumab

Known as: NIVO 
A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death… Expand
National Institutes of Health

Related topics

Related topics

6 relations
10 ML nivolumab 10 MG/ML Injection [Opdivo]Monoclonal AntibodiesNCIt Antineoplastic Agent Terminologyantigen binding

Broader (1)

Antineoplastic Agents

Narrower (1)

MDX-1106

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.
BACKGROUND In the ongoing phase 3 CheckMate 214 trial, nivolumab plus ipilimumab showed superior efficacy over sunitinib in… Expand
Is this relevant?
Review
2019
Review
2019
Combination of CTLA-4 and PD-1 blockers for treatment of cancer
  • Anand Rotte
  • Journal of experimental & clinical cancer…
  • 2019
    • Corpus ID: 189817689
Targeting checkpoints of immune cell activation has been demonstrated to be the most effective approach for activation of anti… Expand
  • table 1
  • table 2
  • figure 1
  • table 3
  • table 4
Is this relevant?
Review
2019
Review
2019
Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy
Immunotherapies have led to substantial changes in cancer treatment and have been a persistently popular topic in cancer research… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
Review
2019
Review
2019
Immunotherapy in colorectal cancer: rationale, challenges and potential
Following initial successes in melanoma treatment, immunotherapy has rapidly become established as a major treatment modality for… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
Is this relevant?
Review
2019
Review
2019
A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated with Immune Checkpoint Inhibitors.
Monoclonal antibodies targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4), programed cell death 1 (PD-1), or its ligand (PD-L1… Expand
Is this relevant?
Review
2019
Review
2019
Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis.
Importance Programmed cell death (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors have been increasingly used in… Expand
Is this relevant?
Review
2019
Review
2019
Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.
BACKGROUND There is no recommended therapy for malignant pleural mesothelioma that has progressed after first-line pemetrexed and… Expand
Is this relevant?
Review
2018
Review
2018
Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non-small cell lung cancer.
OBJECTIVE We conducted a phase I trial of neoadjuvant nivolumab, a monoclonal antibody to the programmed cell death protein 1… Expand
Is this relevant?
Review
2018
Review
2018
Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma
BackgroundTherapeutic chances for metastatic melanoma have consistently changed over the last years with the advent of antibodies… Expand
  • figure 1
  • table 1
  • table 1
  • table 2
  • figure 2
Is this relevant?
Review
2017
Review
2017
Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point 18F-FDG PET/CT Imaging in Patients with Advanced Melanoma
The purpose of this study was to evaluate 18F-FDG PET/CT scanning as an early predictor of response to immune checkpoint… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 2
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE